Johnson & Johnson Retained Earnings (Accumulated Deficit) 2012-2026 | JNJ
Johnson & Johnson retained earnings (accumulated deficit) from 2012 to 2026. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
- Johnson & Johnson retained earnings (accumulated deficit) for the quarter ending March 31, 2026 were $168.978B, a 8.46% increase year-over-year.
- Johnson & Johnson retained earnings (accumulated deficit) for 2025 were $168.978B, a 8.46% increase from 2024.
- Johnson & Johnson retained earnings (accumulated deficit) for 2024 were $155.791B, a 1.27% increase from 2023.
- Johnson & Johnson retained earnings (accumulated deficit) for 2023 were $153.843B, a 19.87% increase from 2022.
|
Johnson & Johnson Annual Retained Earnings (Accumulated Deficit) (Millions of US $) |
|
|---|---|
| 2025 | $168,978 |
| 2024 | $155,791 |
| 2023 | $153,843 |
| 2022 | $128,345 |
| 2021 | $123,060 |
| 2020 | $113,890 |
| 2019 | $110,659 |
| 2018 | $106,216 |
| 2017 | $101,793 |
| 2016 | $110,551 |
| 2015 | $103,879 |
| 2014 | $97,245 |
| 2013 | $89,493 |
| 2012 | $85,992 |
| 2011 | $81,251 |
|
Johnson & Johnson Quarterly Retained Earnings (Accumulated Deficit) (Millions of US $) |
|
|---|---|
| 2025-12-31 | $168,978 |
| 2025-09-30 | $167,281 |
| 2025-06-30 | $165,371 |
| 2025-03-31 | $162,635 |
| 2024-12-31 | $155,791 |
| 2024-09-30 | $155,179 |
| 2024-06-30 | $155,360 |
| 2024-03-31 | $153,378 |
| 2023-12-31 | $153,843 |
| 2023-09-30 | $152,536 |
| 2023-06-30 | $129,381 |
| 2023-03-31 | $124,558 |
| 2022-12-31 | $128,345 |
| 2022-09-30 | $127,917 |
| 2022-06-30 | $126,216 |
| 2022-03-31 | $124,380 |
| 2021-12-31 | $123,060 |
| 2021-09-30 | $121,092 |
| 2021-06-30 | $120,154 |
| 2021-03-31 | $116,508 |
| 2020-12-31 | $113,890 |
| 2020-09-30 | $114,831 |
| 2020-06-30 | $113,898 |
| 2020-03-31 | $112,901 |
| 2019-12-31 | $110,659 |
| 2019-09-30 | $109,242 |
| 2019-06-30 | $109,809 |
| 2019-03-31 | $106,650 |
| 2018-12-31 | $106,216 |
| 2018-09-30 | $107,617 |
| 2018-06-30 | $106,123 |
| 2018-03-31 | $104,339 |
| 2017-12-31 | $101,793 |
| 2017-09-30 | $114,805 |
| 2017-06-30 | $113,208 |
| 2017-03-31 | $111,643 |
| 2016-12-31 | $110,551 |
| 2016-09-30 | $108,860 |
| 2016-06-30 | $106,738 |
| 2016-03-31 | $104,990 |
| 2015-12-31 | $103,879 |
| 2015-09-30 | $102,748 |
| 2015-06-30 | $101,352 |
| 2015-03-31 | $98,656 |
| 2014-12-31 | $97,245 |
| 2014-09-30 | $96,560 |
| 2014-06-30 | $93,745 |
| 2014-03-31 | $91,387 |
| 2013-12-31 | $89,493 |
| 2013-09-30 | $87,703 |
| 2013-06-30 | $89,449 |
| 2013-03-31 | $87,242 |
| 2012-12-31 | $85,992 |
| 2012-09-30 | $84,880 |
| 2012-06-30 | $83,530 |
| 2012-03-31 | $83,103 |
| 2011-12-31 | $81,251 |
| 2011-09-30 | $82,634 |
| 2011-06-30 | $80,836 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $574.358B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |